156 related articles for article (PubMed ID: 16367925)
1. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
[TBL] [Abstract][Full Text] [Related]
2. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.
Kadoch C; Li J; Wong VS; Chen L; Cha S; Munster P; Lowell CA; Shuman MA; Rubenstein JL
Clin Cancer Res; 2014 Feb; 20(4):1029-41. PubMed ID: 24190981
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
Terui Y; Sakurai T; Mishima Y; Mishima Y; Sugimura N; Sasaoka C; Kojima K; Yokoyama M; Mizunuma N; Takahashi S; Ito Y; Hatake K
Cancer Sci; 2006 Jan; 97(1):72-9. PubMed ID: 16367924
[TBL] [Abstract][Full Text] [Related]
5. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
6. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
7. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
Miyake Y; Okoshi Y; Machino T; Chiba S
Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
[TBL] [Abstract][Full Text] [Related]
8. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
Harjunpää A; Wiklund T; Collan J; Janes R; Rosenberg J; Lee D; Grillo-López A; Meri S
Leuk Lymphoma; 2001 Aug; 42(4):731-8. PubMed ID: 11697503
[TBL] [Abstract][Full Text] [Related]
9. Secondary central nervous system lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
[TBL] [Abstract][Full Text] [Related]
10. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
11. Complement activation determines the therapeutic activity of rituximab in vivo.
Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
13. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
14. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.
Schulz H; Pels H; Schmidt-Wolf I; Zeelen U; Germing U; Engert A
Haematologica; 2004 Jun; 89(6):753-4. PubMed ID: 15194546
[TBL] [Abstract][Full Text] [Related]
15. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Hong SJ; Kim JS; Chang JH; Kim KM; Kim SJ; Lee HW; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2009 Apr; 50(2):280-3. PubMed ID: 19430564
[TBL] [Abstract][Full Text] [Related]
16. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.
Strowd RE; Abuali IA; Grossman SA
CNS Oncol; 2015; 4(3):131-5. PubMed ID: 25905905
[TBL] [Abstract][Full Text] [Related]
17. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
18. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS; Glennie MJ
Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
[TBL] [Abstract][Full Text] [Related]
19. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
20. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
